# AURORAS-1 (NCT06983743)

> A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06983743
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Erasca, Inc.
- Conditions: Metastatic Solid Tumors
- Interventions: ERAS-0015; ERAS-0015 in combination
- Enrollment: 600
- Primary outcome: Dose Limiting Toxicities (DLT)
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Recommended dose for expansion (RDE)
- Primary outcome: Adverse Events
- Primary outcome: Plasma concentration (Cmax)
- Primary outcome: Time to achieve Cmax (Tmax)
- Primary outcome: Area under the curve
- Primary outcome: Half-life

## Indexed commentary on AURORAS-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=auroras-1-nct06983743